Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 GlobeNewswire - Thu Jun 26, 3:30PM CDT

CLLS : 1.5900 (-3.64%)
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025 GlobeNewswire - Wed May 21, 3:30PM CDT

CLLS : 1.5900 (-3.64%)
Cellectis Reports Financial Results for the First Quarter 2025 GlobeNewswire - Mon May 12, 3:30PM CDT

CLLS : 1.5900 (-3.64%)
Cellectis to Report First Quarter Financial Results on May 12, 2025 GlobeNewswire - Tue May 6, 3:30PM CDT

CLLS : 1.5900 (-3.64%)
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting GlobeNewswire - Mon Apr 28, 3:30PM CDT

CLLS : 1.5900 (-3.64%)
Author
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal MarketBeat - Tue Apr 22, 8:00AM CDT

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

AZN : 71.13 (-0.95%)
CLLS : 1.5900 (-3.64%)
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update GlobeNewswire - Thu Mar 13, 5:07PM CDT

CLLS : 1.5900 (-3.64%)
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 GlobeNewswire - Fri Mar 7, 3:30PM CST

CLLS : 1.5900 (-3.64%)
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 GlobeNewswire - Mon Feb 24, 12:30AM CST

CLLS : 1.5900 (-3.64%)
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't?
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? Zacks Investment Research - Tue Jan 7, 11:38AM CST

Investors in Cellectis S.A. CLLS need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $5 Call had some of the highest implied volatility...

CLLS : 1.5900 (-3.64%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In? Barchart - Sat Jul 12, 2:47PM CDT
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot